ASTRAZENECA PLC |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,049 GBX | +0.51% |
|
+6.88% | +13.43% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
2024-04-28
- Roadshow - Day 1
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
149.3
USD
Average target price
164.3
USD
Spread / Average Target
+10.02%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +13.43% | 231B | |
| +25.72% | 661B | |
| +26.74% | 566B | |
| -6.56% | 352B | |
| +20.42% | 332B | |
| +3.01% | 283B | |
| +4.70% | 200B | |
| -9.41% | 195B | |
| -5.10% | 145B | |
| -10.59% | 144B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- AstraZeneca : Ordered by Brussels Court to Deliver 80.2 Million COVID-19 Jabs to EU
